Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Eisai presentations at the Annual Meeting of the American Academy of Neurology highlight key data supporting real-world retention rates and long-term seizure-freedom rates with FYCOMPA

Posted on: 22 Apr 18

WOODCLIFF LAKE, N.J., April 19, 2018 /PRNewswire/ -- Eisai Inc. will present six posters on FYCOMPA® (perampanel) CIII  at the American Academy of Neurology (AAN) Annual Meeting in Los Angeles from April 21-27. The poster presentations will include analyses on long-term convulsive seizure-freedom and retention rates for FYCOMPA, as well as data on the use of FYCOMPA as monotherapy for partial seizures.

On July 26, 2017, FYCOMPA was approved as monotherapy for the treatment of partial-onset seizures (POS) with or without secondarily generalized (SG) seizures in patients with epilepsy 12 years of age or older; in addition to the monotherapy use in POS, FYCOMPA is approved for adjunctive use for POS and primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy 12 years of age and older. On March 30, 2018, Eisai submitted a supplemental new drug application (sNDA) for priority review to the U.S. Food and Drug Administration (FDA) for FYCOMPA as monotherapy and adjunctive use for the treatment of POS with or without SG seizures in pediatric patients (ages 2 to less than 12 years). The submission also proposed a pediatric indication for monotherapy and adjunctive use for PGTC seizures in children (ages 2 to less than 12 years) with epilepsy. The sNDA is for both the FYCOMPA tablet and oral suspension formulations. FYCOMPA is approved in 55 countries and has been prescribed to more than 100,000 patients worldwide across all indications.

"As a company, we are constantly striving to provide new solutions for those living with epilepsy and increase the breadth of patients for which FYCOMPA may provide seizure-freedom," said Lynn Kramer, M.D., Chief Clinical Officer and Chief Medical Officer, Neurology Business Group, Eisai. "We are committed to exploring treatment options for patients across the age spectrum, and I am excited to be presenting data that could affect their treatment to our peers at AAN."

"I am encouraged to share the results of an interim analysis showing that over half of patients with epilepsy receiving FYCOMPA as part of routine clinical care remained on the treatment at the two year mark," said Robert T. Wechsler, MD, PhD, Medical Director, Idaho Comprehensive Epilepsy Center. "It is invaluable to the medical community to have access to real-world data on the treatments that directly affect the lives of our patients living with epilepsy, a condition in which poor antiepileptic drug adherence can lead to issues such as breakthrough seizures, putting patients at risk for sudden unexpected death in epilepsy (SUDEP). As an epileptologist, even one seizure for my patients is too many."

Editor's Details

Mike Wood

Last updated on: 22/04/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.